276 related articles for article (PubMed ID: 30634950)
41. Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review.
Sasano H; Sekine A; Hirata T; Iwamoto K; Itou Y; Itani H; Kondou S; Tokui T; Tanigawa M
Intern Med; 2018 Nov; 57(22):3271-3275. PubMed ID: 29984766
[TBL] [Abstract][Full Text] [Related]
42. Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue.
Deftereos G; Sandoval A; Furtado LV; Bronner M; Matynia AP
Hum Pathol; 2020 Mar; 97():52-59. PubMed ID: 31978505
[TBL] [Abstract][Full Text] [Related]
43. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature.
Luo W; Lindley SW; Lindley PH; Krempl GA; Seethala RR; Fung KM
Int J Clin Exp Pathol; 2014; 7(12):9008-22. PubMed ID: 25674280
[TBL] [Abstract][Full Text] [Related]
44. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
[TBL] [Abstract][Full Text] [Related]
45. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
46. Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis.
Sun W; Feng L; Yang X; Li L; Liu Y; Lv N; Lin D
Hum Pathol; 2018 Nov; 81():261-271. PubMed ID: 30420048
[TBL] [Abstract][Full Text] [Related]
47. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
48. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
49. Clonally-related primary ALK rearranged adenocarcinoma and associated metastatic lesions.
Zhu YC; Deng YT; Wang WX; Xu CW; Zhuang W; Du KQ
Thorac Cancer; 2018 Jul; 9(7):881-884. PubMed ID: 29737033
[TBL] [Abstract][Full Text] [Related]
50. ALK-positive adenocarcinoma of the lung expressing neuroendocrine markers and presenting as a "pituitary adenoma".
Mengoli MC; Bertolini F; Maur M; Barbieri F; Longo L; Gasparri P; Tiseo M; Rossi G
Pathologica; 2017 Dec; 109(4):408-411. PubMed ID: 29449735
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemistry Profile Predicts
Li W; Niehaus AG; O'Neill SS
Int J Surg Pathol; 2020 Aug; 28(5):502-506. PubMed ID: 32114861
[TBL] [Abstract][Full Text] [Related]
52. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
[TBL] [Abstract][Full Text] [Related]
53. ALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma.
Vaidya PJ; Kate AH; Mehta D; Dhabar BN; Chhajed PN
J Cancer Res Ther; 2016; 12(2):1090-2. PubMed ID: 27461706
[TBL] [Abstract][Full Text] [Related]
54. Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.
Wang LL; Ding L; Zhao P; Guan JJ; Ji XB; Zhou XL; Shao SH; Zou YW; Fu WW; Lin DL
Dis Markers; 2021; 2021():9186056. PubMed ID: 34234879
[TBL] [Abstract][Full Text] [Related]
55. Using Disposable Membrane Cell Collector to Enrich Lung Adenocarcinoma Cells in Bloody Pleural Effusion for Anaplastic Lymphoma Kinase Fusion Gene Detection.
Guo X; Zhao J; Du Y; Liu Y; Ma Y; Wang R; Ji X; Wu J; Dong L
Acta Cytol; 2021; 65(3):235-241. PubMed ID: 33631757
[TBL] [Abstract][Full Text] [Related]
56. Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.
Miller TE; Yang M; Bajor D; Friedman JD; Chang RYC; Dowlati A; Willis JE; Sadri N
J Clin Pathol; 2018 Dec; 71(12):1108-1115. PubMed ID: 30228211
[TBL] [Abstract][Full Text] [Related]
57. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma.
Zhang P; Wu X; Tang M; Nie X; Li L
Thorac Cancer; 2019 Dec; 10(12):2218-2224. PubMed ID: 31602787
[TBL] [Abstract][Full Text] [Related]
58. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature.
Thumallapally N; Yu H; Farhan M; Ibrahim U; Odiami M
J Pharm Pract; 2018 Apr; 31(2):244-248. PubMed ID: 28438075
[TBL] [Abstract][Full Text] [Related]
59. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.
Lee JG; Kim S; Shim HS
Lung Cancer; 2012 Jul; 77(1):156-61. PubMed ID: 22418245
[TBL] [Abstract][Full Text] [Related]
60. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
